PETER TOTHY, MD

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Established patient office or other outpatient visit, 40-54 minutes

Injection, carboplatin, 50 mg

Flow cytometry technique for dna or cell analysis, first marker

Administration of additional new drug or substance into vein using push technique

Infusion into a vein for hydration, 31-60 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Established patient office or other outpatient visit, 30-39 minutes

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Flow cytometry technique for dna or cell analysis, each additional marker

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Administration of chemotherapy into vein, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Established patient office or other outpatient visit, 20-29 minutes

Injection, pembrolizumab, 1 mg

Injection, palonosetron hcl, 25 mcg

Irrigation of implanted venous access drug delivery device

Injection of additional new drug or substance into vein

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Application of on-body injector for under skin injection

Carcinoembryonic antigen (cea) protein level

Injection of drug or substance under skin or into muscle

Beta-2 microglobulin (protein) level

Injection, eflapegrastim-xnst, 0.1 mg

Psa (prostate specific antigen) measurement, total

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Blood test, thyroid stimulating hormone (tsh)

Injection, ferric derisomaltose, 10 mg

Cyanocobalamin (vitamin b-12) level

Folic acid level, serum

Injection, denosumab, 1 mg

Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

Ferritin (blood protein) level

Gammaglobulin (immune system protein) measurement

Total protein level, blood

Injection, oxaliplatin, 0.5 mg

Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count

Iron binding capacity

Liver enzyme (sgot), level

Lactate dehydrogenase (enzyme) level

Blood creatinine level

Calcium level, total

Blood sodium level